Uridine triacetate

Last updated

Uridine triacetate
Uridine triacetate structure.svg
Clinical data
Trade names Vistogard, Xuriden
Other namesvistonuridine
AHFS/Drugs.com Monograph
MedlinePlus a616020
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism Pyrimidine catabolic pathway
Onset of action Tmax = 2–3 hours
Elimination half-life 2–2.5 hours
Excretion Kidney
Identifiers
  • [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.021.710 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C15H18N2O9
Molar mass 370.314 g·mol−1
3D model (JSmol)
  • CC(=O)OCC1C(C(C(O1)N2C=CC(=O)NC2=O)OC(=O)C)OC(=O)C
  • InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1
  • Key:AUFUWRKPQLGTGF-FMKGYKFTSA-N

Uridine triacetate (INN), [1] formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine [2] used:

Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015. [9] [10] [11]

References

  1. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. p. 92. Retrieved 12 March 2017.
  2. ↑ "Uridine triacetate — DrugBank Page". 12 March 2017.
  3. ↑ "Xuriden- uridine triacetate granule". DailyMed. 16 December 2019. Retrieved 20 October 2020.
  4. ↑ "Vistogard- uridine triacetate granule". DailyMed. 15 November 2018. Retrieved 20 October 2020.
  5. ↑ "BTG Announces FDA Approval of Vistogard (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine". BTG International Ltd. 11 December 2015. Retrieved 12 March 2017.
  6. ↑ "Approved Drugs — Uridine Triacetate". U.S. Food and Drug Administration. Archived from the original on 3 March 2016. Retrieved 12 March 2017.
  7. ↑ Cada DJ, Mbogu U, Bindler RJ, Baker DE (June 2016). "Uridine Triacetate". Hospital Pharmacy. 51 (6): 484–8. doi:10.1310/hpj5106-484. PMC   4911989 . PMID   27354750.
  8. ↑ Ison G, Beaver JA, McGuinn WD, Palmby TR, Dinin J, Charlab R, et al. (September 2016). "FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs". Clinical Cancer Research. 22 (18): 4545–4549. doi: 10.1158/1078-0432.CCR-16-0638 . PMID   27401247. S2CID   25746700.
  9. ↑ "Xuriden (uridine triacetate) oral granules". U.S. Food and Drug Administration (FDA). 8 October 2015. Archived from the original on 8 December 2019. Retrieved 7 December 2019.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  10. ↑ "Drug Trials Snapshots: Xuriden". U.S. Food and Drug Administration (FDA). 4 September 2015. Archived from the original on 8 December 2019. Retrieved 8 December 2019.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  11. ↑ "Previous Cumulative CY CDER BT Approvals" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 8 December 2019. Retrieved 7 December 2019.PD-icon.svg This article incorporates text from this source, which is in the public domain .


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.